With prolonged use of quetiapine potential exists for the development of tardive dyskinesia. If you have any symptoms of tardive dyskinesia is necessary to reduce the dose or discontinue further treatment with quetiapine.
With a sharp lifting of high doses of antipsychotic drugs may be observed following acute reactions (withdrawal syndrome) – nausea, vomiting, insomnia rarely.
Reported cases of exacerbation deca durabolin injection of psychotic symptoms and the emergence of involuntary movement disorders (akathisia, dystonia, dyskinesia). In this connection, the abolition of the drug is recommended to be made gradually.
Data on overdose of Seroquel limited. Cases of quetiapine in doses greater than 20 g, without fatal consequences and with full recovery, but there are reports of very rare cases quetiapine overdose, resulting in death or coma.
Symptoms: The symptoms reported were mainly a consequence of strengthening the known pharmacological effects of the drug such as drowsiness and excessive sedation, tachycardia and lowering blood pressure.
Treatment: No specific antidote to quetiapine. In cases of severe intoxication should be considered symptomatic therapy is recommended to carry out activities aimed at the maintenance of respiratory function, cardiovascular system, ensuring adequate oxygenation and ventilation. A careful medical supervision and monitoring should be continued until the patient’s full recovery.
INTERACTION WITH OTHER LEKARSTVNNYMI funds and other forms of interaction
With simultaneous administration of these drugs possessing a strong inhibitory effect on deca durabolin injection(antifungal agents such as azoles and macrolide group of antibiotics), quetiapine plasma concentration may be increased. In such cases it is necessary to use lower doses of quetiapine. Particular attention should be given to the elderly and immunocompromised patients. You must individually assess the risk-benefit ratio for each patient. Co-administration of quetiapine with drugs that induce liver enzyme system, such as carbamazepine, may reduce plasma concentrations that may require increased doses of Seroquel, depending on the clinical effect.
The pharmacokinetics study in various quetiapine dosage when assigning it before or simultaneously with carbamazepine (an inducer of hepatic enzymes), such co-administration resulted in a significant increase in the clearance of quetiapine. This increase in decreased clearance of quetiapine on average 13% compared to the use of quetiapine without carbamazepine. Co-administration of quetiapine with other inducers of microsomal liver enzymes – phenytoin, also led to an increase in the clearance of quetiapine. When concomitant administration of quetiapine and phenytoin (or other hepatic enzyme inducers such as barbiturates, rifampicin) may require increased doses of Seroquel. You may also need to reduce the dose of quetiapine with phenytoin or carbamazepine the abolition or another inducer of liver enzyme system or replacement of the drug without inducing hepatic microsomal enzymes (eg sodium valproate).
The pharmacokinetics of lithium products does not change with concomitant administration of quetiapine.
There were no clinically relevant changes in the pharmacokinetics of valproic acid and quetiapine with a joint appointment divalproeksa sodium (sodium valproate and valproic acid in a molar ratio of 1: 1) and Seroquel (quetiapine).
Quetiapine does not cause induction of hepatic enzyme systems involved in the metabolism of antipyrine.
The pharmacokinetics of quetiapine were not significantly changed, while the appointment with the antipsychotics risperidone or haloperidol. However, concomitant use of quetiapine and thioridazine led to an increase in the clearance of quetiapine.
Is a key enzyme involved in cytochrome metabolism of quetiapine. The pharmacokinetics of quetiapine were not significantly changed by the simultaneous application of cimetidine, an inhibitor.
The pharmacokinetics of quetiapine were not significantly altered, while the appointment of the antidepressant imipramine or fluoxetine . However, it is advisable to be careful at simultaneous use of quetiapine and systemic use of strong inhibitors of deca durabolin injection (such as azole antifungals and macrolide group of antibiotics).
Drugs that suppress the central nervous system, and ethanol increase the risk of side effects.
Quetiapine may induce orthostatic hypotension, especially during deca durabolin injection the initial dose-titration period (observed in elderly patients are more likely than younger people). eq 300 mg